Comparative Safety Surveillance of Triple (IDA) Versus Dual Therapy (DA) in Mass Drug Administration for Elimination of Lymphatic Filariasis in Kenya: A Cohort Event Monitoring Study

Christabel Khaemba (), Abbie Barry (), Wyckliff P. Omondi (), Elvis Kirui (), Margaret Oluka (), Gurumurthy Parthasarathi (), Sammy M. Njenga (), Anastacia Guantai () and Eleni Aklillu ()
Additional contact information
Christabel Khaemba: Karolinska Institutet
Abbie Barry: Karolinska Institutet
Wyckliff P. Omondi: Ministry of Health, National Neglected Tropical Diseases Program
Elvis Kirui: Ministry of Health, National Public Health Laboratory
Margaret Oluka: University of Nairobi
Gurumurthy Parthasarathi: Botswana Medicines Regulatory Authority
Sammy M. Njenga: Kenya Medical Research Institute (KEMRI)
Anastacia Guantai: University of Nairobi
Eleni Aklillu: Karolinska Institutet

Drug Safety, 2023, vol. 46, issue 10, No 4, 974 pages

Abstract: Abstract Introduction Dual diethylcarbamazine and albendazole (DA) therapy is the standard mass drug administration (MDA) regimen for lymphatic filariasis in Kenya. Following the recent World Health Organization recommendation, Kenya piloted triple therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) in MDA. Objective We conducted a community-based, observational, cohort event monitoring study to compare the types, frequency, severity, and predictors of adverse events following dual versus triple therapy in 20,421 eligible residents. Methods Residents in Kilifi (n = 10,010) and Mombasa counties (n = 10,411) received DA and IDA through MDA campaigns, respectively. Adverse events were actively monitored through house-to-house visits on days 1, 2, and 7 after MDA. Any clinical events reported before and after MDA were cross-checked and verified to differentiate pre-existing events from MDA-associated adverse events. Results Overall, 5807 and 3102 adverse events were reported by 2839 and 1621 individuals in the IDA and DA groups, respectively. The incidence of experiencing one or more adverse events was significantly higher (p

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-023-01338-9 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:46:y:2023:i:10:d:10.1007_s40264-023-01338-9

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-023-01338-9

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().